Does Medicare Cover Otezla?

If you’ve ever picked up a script for Otezla under commercial insurance, you might remember the drug as “the one with the manufacturer copay card that brought my cost down to $0.” Then you turned 65, transitioned to Medicare, and discovered that the manufacturer card no longer applies. The first month’s bill arrived. It was a lot.

This is the most common painful moment in Medicare specialty drug coverage. Otezla is covered. It’s on the formulary. Your prescription is valid. But the out-of-pocket math under Medicare is dramatically different from what most patients experience under commercial insurance, because two protections disappear simultaneously: manufacturer copay assistance becomes illegal under federal anti-kickback rules, and the drug usually lands on the specialty tier instead of the preferred-brand tier.

The good news is the Inflation Reduction Act capped your annual exposure starting in 2025. The bad news is you’ll still feel the cap getting hit hard in February or March if you’re new to Otezla on Medicare.

What Otezla is approved for, and why that matters

Otezla (apremilast) is an oral PDE4 inhibitor manufactured by Amgen. The FDA has approved it for three indications:

• Moderate-to-severe plaque psoriasis in adults
• Active psoriatic arthritis in adults
• Oral ulcers associated with Behçet’s disease in adults

When prescribed for any of these three indications, Medicare Part D plans are required to provide coverage as part of the protected immunology drug class. That doesn’t mean it’s affordable — just that the door isn’t closed. The economic experience after walking through the door depends on tier placement, prior authorization, step therapy, and the new annual cap.

Why specialty tier changes everything

Most Part D plans use a five-tier formulary structure:

• Tier 1: Preferred generics ($0–$5 typical copay)
• Tier 2: Generic ($5–$15 copay)
• Tier 3: Preferred brand ($30–$50 copay or 25% coinsurance)
• Tier 4: Non-preferred brand ($90+ copay or 30–40% coinsurance)
• Tier 5: Specialty (25–33% coinsurance, no flat copay option)

Otezla typically lands on Tier 5. The reason is bureaucratic but consequential: any drug whose negotiated Part D price exceeds the specialty tier threshold (around $590/month in 2026) can be placed on Tier 5. Otezla’s price is roughly $4,500/month at the wholesale acquisition level. Plans see the price and class it specialty.

Tier 5 means coinsurance — a percentage of the drug’s price — not a flat copay. If your plan’s specialty coinsurance is 33%, that’s roughly $1,500 out of pocket for a single one-month fill before any other adjustments.

How the $2,000 annual cap reshapes the cost story

Here’s the part that improved meaningfully starting in 2025.

Under the old Part D structure, specialty drug users routinely spent $5,000 to $10,000 per year out of pocket because the catastrophic phase still required 5% coinsurance with no upper limit. The Inflation Reduction Act eliminated that.

Now your annual out-of-pocket spending on Part D drugs is capped at $2,000, period. For a Tier 5 drug like Otezla, this changes the year as follows:

• Month 1: You meet the deductible (capped at $590 in 2026) and pay the deductible amount, plus partial coinsurance after the deductible. Typical out-of-pocket: $1,200–$1,500.
• Month 2: Continued coinsurance. Typical out-of-pocket: $500–$800. By the end of month 2 or early in month 3, you’ve hit the $2,000 cap.
• Months 3 through 12: $0.

This is a dramatic change from prior years and worth understanding fully. If you’re on Otezla, your year is structured as: pay heavy in Q1, pay nothing the rest of the year. Plan your finances around the front-loading.

Prior authorization and step therapy realities

Most Part D plans require prior authorization for Otezla. The PA submission asks for documentation of:

• Confirmed diagnosis (psoriasis, psoriatic arthritis, or Behçet’s)
• Severity (Body Surface Area for psoriasis, joint count for PsA)
• Prior therapies tried and failed (or contraindicated)

Step therapy requirements vary by plan. Common patterns:

• Plaque psoriasis: Topical corticosteroids → topical vitamin D analogs → phototherapy or systemic therapy → biologic or Otezla
• Psoriatic arthritis: NSAIDs → conventional DMARD (typically methotrexate) → biologic or Otezla
• Behçet’s: Topical corticosteroids → systemic corticosteroids or colchicine → Otezla

If you’ve already gone through these steps under prior coverage, your prescriber’s office should be able to document that history and satisfy step therapy quickly. The friction point comes when patients move to Medicare from commercial insurance and the new plan can’t see the prior treatment history.

A practical tip: ask your dermatologist or rheumatologist’s office to print a one-page treatment summary covering everything you’ve tried. That summary becomes the foundation of the PA submission.

Generic apremilast: the changing picture

Until recently, Otezla had no generic. That changed in 2025 when the first generic apremilast products entered the market following patent settlements with Amgen.

If you’re newly starting therapy in 2026, expect generic apremilast to be available at most major pharmacies and likely placed on Tier 4 or even Tier 2 by many Part D plans by mid-2026. The cost difference is meaningful: a Tier 2 generic typically runs $10–$15 per month after deductible, versus 33% coinsurance on Tier 5. If your prescription is currently for brand Otezla, ask your prescriber whether switching to generic apremilast is appropriate. For most patients, the answer is yes.

Side effects and Medicare’s coverage of related care

Otezla’s most common side effects are gastrointestinal — diarrhea, nausea, headache, and weight loss in the first weeks of therapy. The titration pack manages most of this; the standard 5-day titration ramp is well-established and usually adequate.

If side effects force discontinuation, Medicare covers the appropriate alternative — biologics like Tremfya, Cosentyx, or Stelara, all of which are also on specialty tiers. Switching between specialty drugs requires a fresh PA with each one, but the underlying coverage logic is the same.

Some patients also need lab monitoring on Otezla — particularly if there’s significant weight loss or signs of depression, which is a labeled warning. Medicare Part B covers these office-administered lab tests with the standard 20% coinsurance. If you have a Medigap policy, that 20% is also covered.

Bottom line

Otezla is covered by Medicare Part D for psoriasis, psoriatic arthritis, and Behçet’s disease — but the structure of the coverage means your first two months of the year will be expensive, with the rest of the year at $0 once you hit the $2,000 cap. Generic apremilast is now changing the math for new prescriptions, often substantially. Talk to your prescriber about generic substitution and confirm formulary placement before the first fill, and the year becomes manageable.